Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

CRISPLD2, a novel insulin-sensitizing adipokine that alters adipocyte size.

Griesel BA., Williams K., Ahsan N., Scherer PE., Olson AL., Sparling DP.

Animal Study on Type 2 Diabetes, published in Obesity (Silver Spring) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Obesity (Silver Spring) (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40855979
DOI
10.1002/oby.24342
Citations
2

Abstract (original English)

Objective Both obesity and adipose tissue fibrosis are associated with insulin resistance, which can improve with weight loss. We previously found increased adipocyte-specific secretion of the novel adipokine CRISPLD2 during weight loss. In this study, we further explore the function of adipose CRISPLD2, which others suggest may regulate inflammation and fibrosis in a variety of tissues. Methods We designed mice with adipose-specific doxycycline-inducible overexpression of CRISPLD2 (CLD2 AD ) to assess adipose-specific effects on tissue structure and function on chow or high-fat diets. The effects of prolonged excess CRISPLD2 were determined after 7 months, including stromal vascular fraction analysis by single-cell RNA-seq. CRISPLD2 cell surface signaling was explored in 3T3-L1 adipocytes via transwell assays, and adipocyte binding partners were determined in unbiased binding screening by mass spectrometry. Results CLD2 AD mice had decreased adipocyte size but unchanged fat mass. Long-term CRISPLD2 overexpression led to downregulation of collagen transcription and decreased fibrosis. CRISPLD2 induced Ifng transcription in adipocytes in vitro and bound multiple adipocyte cell surface proteins, including nucleolin. Finally, obese CLD2 AD mice had decreased adipocyte size and improved glucose tolerance, with no change in fat mass. Conclusions These data suggest a model wherein CR

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsAdipocytesMiceInsulin Resistance3T3-L1 CellsObesityCell Adhesion MoleculesDiet, High-FatAdipokinesMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research